Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Completed · Phase 2

Conditions studied: Hand Eczema

In brief

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Key facts

Study ID

NCT05906628

Run by

Incyte Corporation

People needed

186

Starts

2023-07-31

Expected to finish

2024-12-13

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares within the previous 12 months.
• Screening and baseline IGA-CHE 3 or 4.
• Baseline CHE-related Itch NRS ≥ 4.
• Have been treated with at least 1 prescription CHE therapy or if such therapy was not advisable or contraindicated.
• Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.

You may not qualify if…

• Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
• Any serious illness or medical, physical, or psychiatric condition(s).
• Laboratory values outside of the protocol-defined criteria.
• Use of protocol-defined treatments within the indicated washout period before baseline.
• Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
• Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
• Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it is running

• Southwest Skin Specialists Phoenix Biltmore — Phoenix, Arizona, United States
• First Oc Dermatology — Fountain Valley, California, United States
• Marvel Clinical Research Llc — Huntington Beach, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Skin Research of South Florida, Llc — Miami, Florida, United States
• Well Pharma Medical Research Corporation — Miami, Florida, United States
• Forcare Clinical Research — Tampa, Florida, United States
• Midwest Allergy Sinus Asthma, Sc — Normal, Illinois, United States
• The Indiana Clinical Trials Center Ictc — Plainfield, Indiana, United States
• Delricht Research — Baton Rouge, Louisiana, United States
• Delricht Research — New Orleans, Louisiana, United States
• Henry Ford Medical Center — Detroit, Michigan, United States
• Jubilee Clinical Research Inc — Las Vegas, Nevada, United States
• Forest Hills Dermatology Group — Kew Gardens, New York, United States
• Juva Skin and Laser Center — New York, New York, United States
• Onsite Clinical Solutions, Llc Charlotte Central Office — Charlotte, North Carolina, United States
• Bexley Dermatology — Bexley, Ohio, United States
• Central Sooner Research — Oklahoma City, Oklahoma, United States
• Oregon Dermatology and Research Center — Portland, Oregon, United States
• Oregon Medical Research Center — Portland, Oregon, United States
• International Clinical Research Tennessee Llc — Murfreesboro, Tennessee, United States
• Austin Institute For Clinical Research Aicr Pflugerville — Pflugerville, Texas, United States
• Dermatology Clinical Research Center of San Antonio — San Antonio, Texas, United States
• Dermatology Research Institute Inc. — Calgary, Alberta, Canada
• Care Clinic — Red Deer, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.